HISA Anti-Doping and Medication Control Rule; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Federal Trade Commission ("Commission") published a document in the Federal Register of October 28, 2022, concerning the Anti-Doping and Medication Control proposed rule submitted by the Horseracing Integrity and Safety Authority. The Authority alerted the Commission that its submission contained an incorrect number. The Commission is issuing this correction to reflect the corrected number.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 213 (Friday, November 4, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 213 (Friday, November 4, 2022)]
[Notices]
[Page 66705]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-24016]
-----------------------------------------------------------------------
FEDERAL TRADE COMMISSION
[File No. P222100]
HISA Anti-Doping and Medication Control Rule; Correction
AGENCY: Federal Trade Commission.
ACTION: Notice of Horseracing Integrity and Safety Authority (HISA)
proposed rule; correction.
-----------------------------------------------------------------------
SUMMARY: The Federal Trade Commission (``Commission'') published a
document in the Federal Register of October 28, 2022, concerning the
Anti-Doping and Medication Control proposed rule submitted by the
Horseracing Integrity and Safety Authority. The Authority alerted the
Commission that its submission contained an incorrect number. The
Commission is issuing this correction to reflect the corrected number.
FOR FURTHER INFORMATION CONTACT: Austin King, Associate General Counsel
for Rulemaking, 202-326-3166, <a href="/cdn-cgi/l/email-protection#5c3d3735323b6f1c3a283f723b332a"><span class="__cf_email__" data-cfemail="0a6b6163646d394a6c7e69246d657c">[email protected]</span></a>, Office of the General
Counsel, Federal Trade Commission, 600 Pennsylvania Avenue NW,
Washington, DC 20580.
SUPPLEMENTARY INFORMATION:
Correction
In FR Doc. 2022-22970 appearing at 87 FR 65292 in the Federal
Register of Friday, October 28, 2022, in the table on page 65365, in
the entry for ``ketoprofen,'' change the first sentence of the final
column, which currently reads [4 ng/mL in serum or plasma.], to read [2
ng/mL in serum or plasma.], which is the amount the Authority intended
to submit but did not because of a typographical error.
Dated: October 31, 2022.
April J. Tabor,
Secretary.
[FR Doc. 2022-24016 Filed 11-3-22; 8:45 am]
BILLING CODE 6750-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.